Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review

Shunde Wang; Xiaoyu Yuan; Zhongjie Shen; Jiaming Zhao; Baishu Zheng; Junyong Zhang; Chengguo Ge

doi:https://doi.org/10.4111/icu.20230015

추천

검색

자료유형: 학술저널

저자정보: Shunde Wang (Department of Urology The ChenJiaqiao Hospital of ShaPingba District of Chongqing City Chongqing China.) Xiaoyu Yuan (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.) Zhongjie Shen (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.) Jiaming Zhao (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.) Baishu Zheng (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.) Junyong Zhang (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.) Chengguo Ge (Department of Urology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.)

저널정보: 대한비뇨기과학회 Investigative and Clinical Urology Investigative and Clinical Urology Vol.64 No.3

발행연도: 2023.5

수록면: 229 - 241 (13page)

DOI: https://doi.org/10.4111/icu.20230015

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

To systematically evaluate the differences in therapeutic response to chemotherapy or immunotherapy between different molecular subtypes of bladder cancer (BC). A comprehensive literature search was performed up to December 2021. Consensus clusters 1 (CC1), CC2 and CC3 molecular subtypes were used to perform meta-analysis. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the therapeutic response by fix-effect modeling. Eight studies involving 1,463 patients were included. For immunotherapy, CC3 showed the highest response rate (CC1 vs. CC3: OR=0.52, 95% CI=0.34–0.78, p=0.002; CC2 vs. CC3: OR=0.42, 95% CI=0.28-0.62, p<0.001), which was mainly reflected in the highest response rate to atezolizumab (CC1 vs. CC3: OR=0.47, 95% CI=0.29–0.75, p=0.002; CC2 vs. CC3: OR=0.38, 95% CI=0.24–0.59, p<0.001). For chemotherapy, CC3 had the lowest response rate to the overall chemotherapy (CC1 vs. CC3: OR=2.05, 95% CI=1.23–3.41, p=0.006; CC2 vs. CC3: OR=2.48, 95% CI=1.50–4.10, p<0.001). Compared with CC2, CC3 responded poorly to both neo-adjuvant chemotherapy (NAC) (OR=1.93, 95% CI=1.09–3.41, p=0.020) and chemoradiation therapy (CRT) (OR=6.07, 95% CI=1.87–19.71, p<0.001). Compared with CC1, CC3 only showed a poorer response to CRT (OR=4.53, 95% CI=1.26–16.27, p=0.020), and no difference in NAC. Our study suggested that molecular classifications are important predictors of cancer treatment outcomes of BC patients and could identify subgroup patients who are most likely to benefit from specific cancer treatments.

#Bladder cancer #Chemotherapy #Immunotherapy #Molecular typing #Therapeutic effect

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Shunde Wang

소속기관 Department of Urology The ChenJiaqiao Hospital of ShaPingba District of Chongqing City Chongqing China.

주요연구분야 의약학 > 임상의학 > 비뇨기과학

논문수 1 이용수 2

Xiaoyu Yuan